Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$0.77 USD
+0.01 (0.97%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.77 0.00 (-0.18%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IRWD 0.77 +0.01(0.97%)
Will IRWD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRWD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRWD
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
IRWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
Other News for IRWD
Vanguard Group Inc. Expands Stake in Ironwood Pharmaceuticals
Ardelyx: 'Hold' With Caution As Major Inflection Point Approaches
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
Ironwood Pharma Elects Directors at Annual Meeting